[1] Wetmore JB, Mahnken JD, Rigler SK, et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients[J]. Kidney Int, 2012, 81(5):469-476. [2] Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation:the atherosclerosis risk in communities (ARIC) study[J]. Circulation, 2011, 123(25):2946-2953. [3] Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney dis-ease and prevalent atrial fibrillation:the chronic renal insufficiency cohort (CRIC)[J]. Am Heart J, 2010, 159(6):1102-1107. [4] Wetmore JB, Ellerbeck EF, Mahnken JD, et al. Atrial fibrillation and risk of stroke in dialysis patients[J]. Ann Epidemiol, 2013, 23(3):112-118. [5] Banerjee A, Fauchier L, Vourc'h P, et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation:the Loire Valley Atrial Fibrillation Project[J]. J Am Coll Cardiol, 2013, 61(20):2079-2087. [6] Kornej J, Hindricks G, Kosiuk J, et al. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation:the Leipzig Heart Center AF Ablation Registry[J]. Circ Arrhythm Electrophysiol, 2013, 6(5):868-874. [7] Nakagawa K, Hirai T, Takashima S, et al. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation[J]. Am J Cardiol, 2011, 107(6):912-916. [8] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J]. Circulation, 2014, 130(23):e199-e267. [9] Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD[J]. Kidney Int, 2014, 85(1):49-61. [10] Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation:Virchow's triad revisited[J]. Lancet, 2009, 373(9658):155-166. [11] Eisen A, Haim M, Hoshen M, et al. Estimated glomerular filtration rate within the normal or mildly impaired range and incident non-valvular atrial fibrillation:results from a population-based cohort study[J]. Eur J Prev Cardiol, 2017, 24(2):213-222. [12] European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2010, 31(19):2369-2429. [13] Wang D, Liu M, Hao Z, et al. Association between reduced kidney function and clinical outcomes after ischaemic stroke with atrial fibrillation[J]. Eur J Neurol, 2014, 21(1):160-166. [14] Chao TF, Liu CJ, Tuan TC, et al. Risk and prediction of sudden cardiac death and ventricular arrhythmias for patients with atrial fibrillation a nationwide cohort study[J]. Sci Rep, 2017; 7:46445. [15] Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation:a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis[J]. Circulation, 2014, 129(9):961-970. [16] Bonde AN, Lip GY, Kamper AL, et al. Renal function and the risk of stroke and bleeding in patients with atrial fibrillation:an observational cohort study[J]. Stroke, 2016; 47(11):2707-2713. [17] Lin WY, Lin YJ, Chung FP, et al. Impact of renal dysfunction on clinical outcome in patients with low risk of atrial fibrillation[J]. Circ J, 2014, 78(4):853-858. |